UBE3A and Angelman syndrome: Our study reveals that a single ICV injection of Ube3a-ATS-targeted ASOs to Ube3amΔe6/p+ mice, a new rodent model of Angelman syndrome (Shi et al., 2022), upregulates Ube3a proteins including the critical short isoform and restores the EEG power spectrum and sleep pattern for at least 6 weeks, particularly upon treatment at the juvenile age.